Associate Director of National Intelligence and Chief Information Officer

Sathgen Therapeutics completes dosing of the first two cohorts of healthy volunteers with MSP008-22, a novel anti-viral drug

Retrieved on: 
Thursday, August 10, 2023
Associate Director of National Intelligence and Chief Information Officer, Therapy, CSO, Consultant, COVID-19, Clinical trial, Chemical engineering, Cancer, Viral, Viral disease, Research, GBL, Institute of Chemical Technology, Pandemic, MD, Patient, NCE, Entrepreneurship, Virus, Safety, BD, Pharmaceutical industry, Vaccine

MUMBAI, India, Aug. 10, 2023 /PRNewswire/ -- Sathgen Therapeutics, a division of the leading chemicals conglomerate in India – Godavari Biorefineries Limited (GBL), announced that they completed the dosing of the first two healthy volunteer cohorts in a Phase 1 clinical trial for MSP008-22, their new chemical entity (NCE). The clinical trial program is managed by Clinexel Life Sciences, a renowned clinical research organization in the pharmaceutical sector.

Key Points: 
  • Sathgen is a clinical-stage novel therapeutics venture focused on bringing therapies for difficult-to-treat diseases like viral infections.
  • Their lead molecule, MSP008-22, has widespread anti-viral potential due to its ability to inhibit both viral entry and replication.
  • Professor Sendurai Mani, Associate Director, Legorreta Cancer Center, Brown University; Co-Founder, Sathgen Therapeutics, stated, "Viral diseases with the ability to lead to pandemics have limited treatment options.
  • Mr. Samir Somaiya, Chairman and MD, GBL; Co-Founder, Sathgen Therapeutics, highlighted the company's commitment to research and its goal in discovering therapies for difficult-to-treat diseases.

Wolters Kluwer Offers Advisory Services to Address New Small Business Lending Requirements

Retrieved on: 
Tuesday, August 8, 2023
Banking, Software, Accounting, LGBTQ+, Professional Services, Consumer, Technology, Small Business, Other Consumer, Legal, Women, Finance, Consulting, Associate Director of National Intelligence and Chief Information Officer, CFPB, Small business, CMS, Report, FCC, Table, Risk management, Wolters, Consumer Financial Protection Bureau, Municipal Technical Advisory Service, Dodd–Frank Wall Street Reform and Consumer Protection Act, Geography, Financial adviser, Real estate, Audit

With the finalization of new small business lending requirements announced by the Consumer Financial Protection Bureau (CFPB) in late March, Wolters Kluwer Compliance Solutions is offering U.S. lenders a range of targeted, consultative services to foster and advance compliance under the new rule, which implements Section 1071 of the Dodd-Frank Act.

Key Points: 
  • With the finalization of new small business lending requirements announced by the Consumer Financial Protection Bureau (CFPB) in late March, Wolters Kluwer Compliance Solutions is offering U.S. lenders a range of targeted, consultative services to foster and advance compliance under the new rule, which implements Section 1071 of the Dodd-Frank Act.
  • “The purpose of the small business lending rules is to promote fair access to credit for small business and small farms, thus making full compliance an imperative for financial institutions that are subject to the Section 1071 requirements,” said Jason Keller , Associate Director, Advisory Services, with Wolters Kluwer Compliance Solutions.
  • The Advisory Services team also offers fair lending risk reviews that can help lenders: identify statistically significant disparities in raw and reported small business and small farm lending data relative to proxied demographic data; identify disparate treatment on prohibited bases; and potential redlining risks.
  • The business, which sits within Wolters Kluwer’s Financial & Corporate Compliance (FCC) division, helps these financial institutions efficiently manage risk and regulatory compliance obligations, and gain the insights needed to focus on better serving their customers and growing their business.

SEGA Partners with PowerA on a New Line of Sonic the Hedgehog™ Gaming Accessories

Retrieved on: 
Monday, August 7, 2023
Heart, Associate Director of National Intelligence and Chief Information Officer, Partnership, Friends, PowerA, Xbox Series X and Series S, Sonic the Hedgehog, Hedgehog, Nintendo Switch, Nintendo Switch Lite, SEGA, Video game, Sonic

BURBANK, Calif., Aug. 7, 2023 /PRNewswire/ -- Today, SEGA of America, Inc. and PowerA, a leader in officially licensed gaming accessories, announced a new partnership to create, distribute and sell a line of Sonic the Hedgehog-themed third-party gaming accessories. The initial product-line launches today and includes controllers for Nintendo Switch and Xbox Series X|S, a branded Nintendo Switch Protective Case, as well as a TriFold Game Card Holder for Nintendo Switch cartridges.

Key Points: 
  • BURBANK, Calif., Aug. 7, 2023 /PRNewswire/ -- Today, SEGA of America, Inc. and PowerA, a leader in officially licensed gaming accessories, announced a new partnership to create, distribute and sell a line of Sonic the Hedgehog-themed third-party gaming accessories.
  • The initial product-line launches today and includes controllers for Nintendo Switch and Xbox Series X|S, a branded Nintendo Switch Protective Case, as well as a TriFold Game Card Holder for Nintendo Switch cartridges.
  • "As big fans ourselves, the PowerA team is thrilled to partner with the team at SEGA to bring Sonic the Hedgehog and friends to our controllers and accessories," said Akio Strasser, Senior Global Marketing Director for PowerA.
  • We are excited to be partnering with Power A to bring this core line of gaming peripherals to fans around the world," said Michael Cisneros, Associate Director, Licensing.

Expert Speaker Lineup Revealed for Award Winning RBQM Event

Retrieved on: 
Tuesday, August 1, 2023
Linda, Operation, Associate Director of National Intelligence and Chief Information Officer, Senior, CD, Astellas Pharma, Data management, Tufts Center for the Study of Drug Development, ZS Associates, Vertex, Clinical trial, Quality management, Evolution, Clinical quality management system, Bristol Myers Squibb, Software, Research, ICH, Central Monitoring System, Parexel, AstraZeneca, Marketing, Guidance, Bayer, Alphabet song, Fellow, Drug development, Entrepreneurship, Merck Serono, ZS, Pharmaceutical industry, Management, Fast food, Tutoring, Light

KING OF PRUSSIA, Pa., Aug. 1, 2023 /PRNewswire/ -- CluePoints, the premier provider of Risk-Based Quality Management (RBQM) Software for clinical trials, has revealed the full agenda and speaker lineup for RBQMLive 2023.

Key Points: 
  • Full agenda and keynote speakers announced for industry-leading risk-based quality management event focusing on the global transformation and evolution of RBQM, sponsored by CluePoints.
  • KING OF PRUSSIA, Pa., Aug. 1, 2023 /PRNewswire/ -- CluePoints , the premier provider of Risk-Based Quality Management (RBQM) Software for clinical trials, has revealed the full agenda and speaker lineup for RBQMLive 2023.
  • RBQMLive 2023 is a free, virtual event for anyone working with, interested in, or planning to adopt risk-based approaches to clinical trial management and oversight.
  • We urge everyone to register for the free sessions and gain insight from our fantastic line-up of expert speakers, all leaders in their respective fields."

Expert Speaker Lineup Revealed for Award Winning RBQM Event

Retrieved on: 
Tuesday, August 1, 2023
Linda, Operation, Associate Director of National Intelligence and Chief Information Officer, Senior, CD, Astellas Pharma, Data management, Tufts Center for the Study of Drug Development, ZS Associates, Vertex, Clinical trial, Quality management, Evolution, Clinical quality management system, Bristol Myers Squibb, Software, Research, ICH, Central Monitoring System, Parexel, AstraZeneca, Marketing, Guidance, Bayer, Alphabet song, Fellow, Drug development, Entrepreneurship, Merck Serono, ZS, Pharmaceutical industry, Management, Fast food, Tutoring, Light

KING OF PRUSSIA, Pa., Aug. 1, 2023 /PRNewswire/ -- CluePoints, the premier provider of Risk-Based Quality Management (RBQM) Software for clinical trials, has revealed the full agenda and speaker lineup for RBQMLive 2023.

Key Points: 
  • Full agenda and keynote speakers announced for industry-leading risk-based quality management event focusing on the global transformation and evolution of RBQM, sponsored by CluePoints.
  • KING OF PRUSSIA, Pa., Aug. 1, 2023 /PRNewswire/ -- CluePoints , the premier provider of Risk-Based Quality Management (RBQM) Software for clinical trials, has revealed the full agenda and speaker lineup for RBQMLive 2023.
  • RBQMLive 2023 is a free, virtual event for anyone working with, interested in, or planning to adopt risk-based approaches to clinical trial management and oversight.
  • We urge everyone to register for the free sessions and gain insight from our fantastic line-up of expert speakers, all leaders in their respective fields."

Arthur D. Little Converts to Type C Railway Signalling Inspection Body Under ISO/IEC 17020:2012

Retrieved on: 
Thursday, July 27, 2023
Transport, Rail, Display (zoology), Associate Director of National Intelligence and Chief Information Officer, United Kingdom Accreditation Service, Multimedia, Type, CENELEC, ADL, UKAS, ISA, Safety, Medical device, Audit

Arthur D. Little (ADL) today announced that the United Kingdom Accreditation Service (UKAS) has confirmed its conversion to a Type C railway signalling system independent safety assessor (ISA) and assessment body (AsBo) under ISO/IEC 17020:2012, in accordance with the CENELEC standards EN50126, EN50128 and EN50129.

Key Points: 
  • Arthur D. Little (ADL) today announced that the United Kingdom Accreditation Service (UKAS) has confirmed its conversion to a Type C railway signalling system independent safety assessor (ISA) and assessment body (AsBo) under ISO/IEC 17020:2012, in accordance with the CENELEC standards EN50126, EN50128 and EN50129.
  • View the full release here: https://www.businesswire.com/news/home/20230727457754/en/
    Arthur D. Little Converts to Type C Railway Signalling Inspection Body Under ISO/IEC 17020:2012 (Graphic: Business Wire)
    ISO/IEC 17020:2012 is an internationally recognized standard that assures the compliance, performance and efficiency of an inspection body.
  • Conversion to a Type C inspection body allows ADL to offer this signalling assurance expertise, not just as an ISA and AsBo, but also for broader signalling assurance requirements.
  • "We have built a strong reputation as a leading signalling system independent safety assessor, working with clients on railway systems around the globe," said Clive Adams, Associate Director, Arthur D. Little.

Datassential Unveils Midyear Food & Beverage Industry Trends

Retrieved on: 
Thursday, July 27, 2023
Associate Director of National Intelligence and Chief Information Officer, Food, Drink, Food industry, Eye, Attention, Birria, Tipping, Traction, Restaurant, Growth, AI, Annual report, Social media, Fatigue, Fast food, Food delivery, Customer service

CHICAGO , July 27, 2023 /PRNewswire/ -- Datassential , the leading food and beverage intelligence platform, has released its 2023 Midyear Trend Report, revealing that barbecued chicken wings are the fastest-growing item on menus today, rising a staggering 373% from a year ago.

Key Points: 
  • CHICAGO , July 27, 2023 /PRNewswire/ -- Datassential , the leading food and beverage intelligence platform, has released its 2023 Midyear Trend Report, revealing that barbecued chicken wings are the fastest-growing item on menus today, rising a staggering 373% from a year ago.
  • "We're always excited to showcase the latest food trends we see gaining traction in our Midyear Trend Report," said Mike Kostyo, Associate Director and Trendologist at Datassential.
  • "Understanding what these trends are and how to implement them is critical for food industry professionals to stay ahead of the curve all year long - and to be able to plan for the long term."
  • Download a free preview of the 2023 Midyear Trend Report here and join our webinar featuring these trends.

Sathgen Therapeutics announces dosing of the first patient cohort with MSP008-22, a novel anti-cancer drug

Retrieved on: 
Thursday, July 20, 2023
TNBC, Associate Director of National Intelligence and Chief Information Officer, Therapy, CSO, HER2, Cancer, Research, GBL, New chemical entity, Science, MD, Patient, Drug discovery, BD, Prostate cancer, Vaccine, Pharmaceutical industry

MUMBAI, India, July 20, 2023 /PRNewswire/ -- Sathgen Therapeutics, a division of a leading chemicals conglomerate in India – Godavari Biorefineries Limited (GBL), has announced the completion of the first cohort in a Phase 1 clinical trial for their first-in-class New Chemical Entity, MSP008-22. The clinical trial program is managed by Clinexel Life Sciences, a renowned contract research organization in the health sector.

Key Points: 
  • Sathgen Therapeutics aims to develop MSP008-22 for difficult-to-treat cancers, starting with triple negative breast cancer (TNBC) and prostate cancer as proof-of-principle.
  • MSP008-22 effectively targets treatment-resistant cancer cells in preclinical models, and demonstrates an excellent safety profile with no serious adverse events in the first patient cohort.
  • Professor Sendurai Mani, Associate Director, Legorreta Cancer Center, Brown University, and Scientific Co-Founder, Sathgen Therapeutics, stated, "TNBC is responsible for 30% of breast cancer-related deaths.
  • With over 15 anti-cancer candidates in the pipeline, Sathgen Therapeutics remains committed to advancing cancer therapeutics.

Sathgen Therapeutics announces dosing of the first patient cohort with MSP008-22, a novel anti-cancer drug

Retrieved on: 
Thursday, July 20, 2023
TNBC, Associate Director of National Intelligence and Chief Information Officer, Therapy, CSO, HER2, Cancer, Research, GBL, New chemical entity, Science, MD, Patient, Drug discovery, BD, Prostate cancer, Vaccine, Pharmaceutical industry

MUMBAI, India, July 20, 2023 /PRNewswire/ -- Sathgen Therapeutics, a division of a leading chemicals conglomerate in India – Godavari Biorefineries Limited (GBL), has announced the completion of the first cohort in a Phase 1 clinical trial for their first-in-class New Chemical Entity, MSP008-22. The clinical trial program is managed by Clinexel Life Sciences, a renowned contract research organization in the health sector.

Key Points: 
  • Sathgen Therapeutics aims to develop MSP008-22 for difficult-to-treat cancers, starting with triple negative breast cancer (TNBC) and prostate cancer as proof-of-principle.
  • MSP008-22 effectively targets treatment-resistant cancer cells in preclinical models, and demonstrates an excellent safety profile with no serious adverse events in the first patient cohort.
  • Professor Sendurai Mani, Associate Director, Legorreta Cancer Center, Brown University, and Scientific Co-Founder, Sathgen Therapeutics, stated, "TNBC is responsible for 30% of breast cancer-related deaths.
  • With over 15 anti-cancer candidates in the pipeline, Sathgen Therapeutics remains committed to advancing cancer therapeutics.

Simplilearn Strengthens Its Teams in the US and India Through Key Leadership Appointments

Retrieved on: 
Tuesday, July 18, 2023
Cloud, Grand Valley State University, Learning, Associate Director of National Intelligence and Chief Information Officer, Product marketing, Software as a service, Adviser, University, Partnership, Skillsoft, 2U, University of Notre Dame, Program management, Associate, Organization, Student, Internet, CRM, Knowledge, Growth, IIT Kanpur, Content, LATAM, Management, Tutoring, Tourism, Priyam, Educational technology, Marketing, Supply

These strategic appointments mark a pivotal moment in Simplilearn's ongoing growth strategy, highlighting the company's unwavering commitment to expanding and reinforcing its teams within India and across international markets.

Key Points: 
  • These strategic appointments mark a pivotal moment in Simplilearn's ongoing growth strategy, highlighting the company's unwavering commitment to expanding and reinforcing its teams within India and across international markets.
  • Mr. Priyam Sachan has joined Simplilearn as Vice President, Marketing for India.
  • Mr. Kevin Adams has joined Simplilearn as Vice President, Commercial Sales, in the US.
  • Mr. Priyam Sachan, Vice President, Marketing, India, said, "I am honored and elated to become a part of the Simplilearn family as the VP of Marketing.